$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

$vrdn Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000119312517166522 Filed on May 11, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$718.0K	$462.0K	$2.050M
YoY Change	-65.96%	-77.46%	55.66%
Cost Of Revenue			$629.0K
YoY Change			-17.24%
Gross Profit			$1.421M
YoY Change			155.12%
Gross Profit Margin			69.32%
Selling, General & Admin	$2.580M	$3.280M	$1.502M
YoY Change	46.18%	118.38%	-37.34%
% of Gross Profit			105.7%
Research & Development	$5.487M	$4.120M	$3.466M
YoY Change	63.55%	18.87%	3366.0%
% of Gross Profit			243.91%
Depreciation & Amortization	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	122.22%
% of Gross Profit			7.04%
Operating Expenses	$8.068M	$7.401M	$4.458M
YoY Change	76.74%	66.02%	36.87%
Operating Profit	-$7.350M	-$6.939M	-$3.541M
YoY Change	113.04%	95.96%	35.57%
Interest Expense	$40.00K	-$40.00K	$23.00K
YoY Change	73.91%	-273.91%	4.55%
% of Operating Profit
Other Income/Expense, Net	$102.0K	$30.00K	$7.000K
YoY Change	1033.33%	328.57%
Pretax Income	-$7.310M	-$6.980M	-$3.620M
YoY Change	107.67%	92.82%	37.64%
Income Tax
% Of Pretax Income
Net Earnings	-$7.312M	-$6.980M	-$3.623M
YoY Change	107.49%	92.66%	37.55%
Net Earnings / Revenue	-1018.38%	-1510.82%	-176.73%
Basic Earnings Per Share
Diluted Earnings Per Share	-$5.112M	-$9.065M	-$90.50M
COMMON SHARES
Basic Shares Outstanding	21.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$46.30M	$54.30M	$8.600M
YoY Change	612.31%	531.4%	-35.34%
Cash & Equivalents	$46.34M	$46.34M	$16.96M
Short-Term Investments
Other Short-Term Assets	$2.500M	$2.400M	$400.0K
YoY Change	316.67%	500.0%	33.33%
Inventory			$269.0K
Prepaid Expenses
Receivables	$539.0K	$277.0K	$490.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$49.35M	$56.94M	$9.672M
YoY Change	519.51%	488.7%	-33.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$626.0K	$597.0K	$1.109M
YoY Change	-41.0%	-46.17%	-7.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.00K	$258.0K	$0.00
YoY Change
Total Long-Term Assets	$676.0K	$855.0K	$1.124M
YoY Change	-37.17%	-23.93%	-6.33%
TOTAL ASSETS
Total Short-Term Assets	$49.35M	$56.94M	$9.672M
Total Long-Term Assets	$676.0K	$855.0K	$1.124M
Total Assets	$50.03M	$57.79M	$10.80M
YoY Change	453.26%	435.33%	-31.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$632.0K	$1.125M	$102.0K
YoY Change	572.34%	1002.94%	-74.5%
Accrued Expenses	$4.019M	$4.180M	$1.149M
YoY Change	201.95%	263.79%	43.63%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$1.100M
YoY Change	-100.0%	-100.0%	0.0%
Long-Term Debt Due	$2.000M	$2.000M
YoY Change
Total Short-Term Liabilities	$6.630M	$7.279M	$2.443M
YoY Change	155.29%	197.95%	-2.28%
LONG-TERM LIABILITIES
Long-Term Debt	$1.900M	$2.300M	$0.00
YoY Change
Other Long-Term Liabilities	$189.0K	$174.0K	$14.00K
YoY Change	2262.5%	1142.86%	-86.0%
Total Long-Term Liabilities	$189.0K	$174.0K	$14.00K
YoY Change	2262.5%	1142.86%	-86.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.630M	$7.279M	$2.443M
Total Long-Term Liabilities	$189.0K	$174.0K	$14.00K
Total Liabilities	$8.690M	$9.800M	$2.457M
YoY Change	233.59%	298.86%	-5.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$81.37M	-$74.06M	-$20.73M
YoY Change	250.25%	257.33%
Common Stock	$215.0K	$214.0K	$107.0K
YoY Change	99.07%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.34M	$47.99M	$8.339M
YoY Change
Total Liabilities & Shareholders Equity	$50.03M	$57.79M	$10.80M
YoY Change	453.26%	435.33%	-31.24%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$7.312M	-$6.980M	-$3.623M
YoY Change	107.49%	92.66%	37.55%
Depreciation, Depletion And Amortization	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	122.22%
Cash From Operating Activities	-$7.080M	-$8.183M	-$4.170M
YoY Change	252.24%	96.24%	276.01%
INVESTING ACTIVITIES
Capital Expenditures	-$110.0K	$44.00K	$105.0K
YoY Change		-58.1%	138.64%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$1.280M
YoY Change
Cash From Investing Activities	-$110.0K	$1.236M	-$105.0K
YoY Change		-1277.14%	138.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$40.70M	$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-760.0K	$39.12M	$0.00
YoY Change	1420.0%		-100.0%
NET CHANGE
Cash From Operating Activities	-7.080M	-$8.183M	-$4.170M
Cash From Investing Activities	-110.0K	$1.236M	-$105.0K
Cash From Financing Activities	-760.0K	$39.12M	$0.00
Net Change In Cash	-7.950M	$32.17M	-$4.275M
YoY Change	285.92%	-852.49%	-152.46%
FREE CASH FLOW
Cash From Operating Activities	-$7.080M	-$8.183M	-$4.170M
Capital Expenditures	-$110.0K	$44.00K	$105.0K
Free Cash Flow	-$6.970M	-$8.227M	-$4.275M
YoY Change	246.77%	92.44%	270.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001590750
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21401828	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	MIRAGEN THERAPEUTICS, INC.
CY2016Q1	mgen	Accretionof Offering Costs AccretionofOfferingCosts	12000	USD
CY2017Q1	mgen	Accretionof Offering Costs AccretionofOfferingCosts	5000	USD
CY2016Q4	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	759000	USD
CY2017Q1	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	636000	USD
CY2016Q4	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	0	USD
CY2017Q1	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	184000	USD
CY2016Q4	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	133000	USD
CY2017Q1	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	82000	USD
CY2016Q4	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	1684000	USD
CY2017Q1	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	1869000	USD
CY2017Q1	mgen	Adjustmentsto Additional Paidin Capital Reclassificationof Warrant Liability AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability	51000	USD
CY2017Q1	mgen	Capital Stock Shares Authorized CapitalStockSharesAuthorized	105000000	shares
CY2016Q1	mgen	Conversionof Warrantsto Permanent Equity ConversionofWarrantstoPermanentEquity	0	USD
CY2017Q1	mgen	Conversionof Warrantsto Permanent Equity ConversionofWarrantstoPermanentEquity	51000	USD
CY2016Q4	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	167000	USD
CY2017Q1	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	190000	USD
CY2016Q1	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
CY2017Q1	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
CY2016Q1	mgen	Stock Issuance Costs Incurred During Noncashor Partial Noncash Transaction StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction	0	USD
CY2017Q1	mgen	Stock Issuance Costs Incurred During Noncashor Partial Noncash Transaction StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction	40000	USD
CY2016Q1	mgen	Transferof Stock Issuance Costs Noncashor Partial Noncash Transaction TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction	0	USD
CY2017Q1	mgen	Transferof Stock Issuance Costs Noncashor Partial Noncash Transaction TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction	331000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1007000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1125000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	277000	USD
CY2016Q1	us-gaap	Accretion Expense AccretionExpense	42000	USD
CY2017Q1	us-gaap	Accretion Expense AccretionExpense	32000	USD
CY2016Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	38000	USD
CY2017Q1	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	37000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3909000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4180000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	124000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	496000	USD
CY2016Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	221000	USD
CY2017Q1	us-gaap	Accrued Rent Current AccruedRentCurrent	50000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2558000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	214000	USD
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	4667000	USD
CY2017Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	4167000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	14000	USD
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	11000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2627000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5147000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121841000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	419000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	38000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	268000	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12768000	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2978000	shares
CY2016Q4	us-gaap	Assets Assets	24760000	USD
CY2017Q1	us-gaap	Assets Assets	57794000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	23877000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	56939000	USD
CY2016Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2017Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1280000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21235000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16960000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22104000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54273000	USD
CY2016Q1	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-4275000	USD
CY2017Q1	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	32169000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	833744	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21401828	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	833744	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21401828	shares
CY2016Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2017Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	184000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	31000	USD
CY2017Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	25000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	81000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	73000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.58
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.60
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	928000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	749000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7000000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y8M33D
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	51000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	133000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	82000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	992000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3281000	USD
CY2015	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2016	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2015	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2016	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	235000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	118000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-60000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	257000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-771000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1054000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-173000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	63000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	534000	USD
CY2016Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	89000	USD
CY2017Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	71000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	41000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	38000	USD
CY2016Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
CY2017Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	9705000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	9800000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24760000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57794000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6885000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7279000	USD
CY2016Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	917000	USD
CY2017Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	10000	USD
CY2017Q1	us-gaap	Long Term Debt LongTermDebt	4167000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	667000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2000000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1500000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2820000	USD
CY2017Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	2347000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8183000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4170000	USD
CY2017Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	5000	USD
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	39116000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-105000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1236000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	404000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	391000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	285000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	22000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	77000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	258000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	258000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	174000	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	USD
CY2016Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1176000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	105000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44000	USD
CY2017Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	4458000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	7401000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3541000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6939000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1357000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	277000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-3623000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-6980000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3635000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6985000	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	1076000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	30000	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	4789000	USD
CY2017Q1	us-gaap	Notes Payable NotesPayable	4321000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1969000	USD
CY2017Q1	us-gaap	Notes Payable Current NotesPayableCurrent	1974000	USD
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1753000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2389000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40700000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40703000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	89000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3183000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3224000	USD
CY2017Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	500000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3466000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4120000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	625000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	597000	USD
CY2016Q1	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	0	USD
CY2017Q1	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	76981000	USD
CY2016Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67076000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-74061000	USD
CY2016Q1	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2017Q1	us-gaap	Revenue From Grants RevenueFromGrants	452000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	917000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	462000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	42000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	419000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	204000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	39156000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	89000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-61921000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	47994000	USD
CY2016Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-12000	USD
CY2017Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-5000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	651041	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11555286	shares
CY2017Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject Miragen to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. Miragen maintains deposits in federally insured financial institutions in excess of federally insured limits. Miragen has not experienced any losses in such accounts. Miragen invests its excess cash primarily in deposits and money market funds held with two financial institutions.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miragen’s consolidated financial statements are prepared in accordance with U.S. GAAP, which requires Miragen to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on Miragen’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001193125-17-166522-index-headers.html	Edgar Link	pending
0001193125-17-166522-index.html	Edgar Link	pending
0001193125-17-166522.txt	Edgar Link	pending
0001193125-17-166522-xbrl.zip	Edgar Link	pending
d372009d10q.htm	Edgar Link	pending
d372009dex1012.htm	Edgar Link	pending
d372009dex1013.htm	Edgar Link	pending
d372009dex1014.htm	Edgar Link	pending
d372009dex311.htm	Edgar Link	pending
d372009dex312.htm	Edgar Link	pending
d372009dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mgen-20170331.xml	Edgar Link	completed
mgen-20170331.xsd	Edgar Link	pending
mgen-20170331_cal.xml	Edgar Link	unprocessable
mgen-20170331_def.xml	Edgar Link	unprocessable
mgen-20170331_lab.xml	Edgar Link	unprocessable
mgen-20170331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

2017 Q2 Form 10-Q Financial Statement

#000119312517166522 Filed on May 11, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN Viridian Therapeutics, Inc.\DE Stock $vrdn

2017 Q2 Form 10-Q Financial Statement

#000119312517166522 Filed on May 11, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn